# 2. SYNOPSIS

Sponsor:	Individual Study	(For National			
Shionogi & Co., Ltd.	Table	Authority Use only)			
Shionogi B.V.	Referring to Part of the Dossier				
Name of Finished Product	Volume:	:			
Not applicable					
Name of Active Ingredient:	Page:				
S-217622					
<b>Study Title:</b> A Phase 2/3 Study of S-217622 in Par	ticipants Infected with SA	ARS-CoV-2			
<b>Investigators and Study Centers:</b> Tl 88 sites in Japan (62 sites) and South	nis was a multicenter glob Korea (26 sites) in Phase 2	al study conducted at 2b Part.			
<b>Publication (reference):</b> Not application	ble				
<b>Studied Period:</b> From 03 Jan 2022 (E 2b Part) to 10 Mar 2022 (Last observa	Enrollment date of the first tion date of the last partic	t participant in Phase ipant in Phase 2b Part)			
<b>Phase of Development:</b> Phase 2/3					
<b>Objectives and Endpoints:</b>					
Phase 2a Part; Participants with Mild/	Moderate or Asymptomat	ic SARS-CoV-2			
Infection		Infection			
Objectives         Endpoints					
Objectives	Enc	lpoints			
Objectives Primary	Enc	lpoints			
Objectives           Primary           Common to participants with mild/moderate           syndrome coronavirus 2 (SARS-CoV-2) info	e and with asymptomatic severe	<b>lpoints</b> e acute respiratory			
Objectives           Primary           Common to participants with mild/moderate syndrome coronavirus 2 (SARS-CoV-2) infer           • To investigate the antiviral effect of 5-d administration of S-217622 in participation with SARS-CoV-2 infection.	e and with asymptomatic severa ection <sup>a</sup> lay nts Change from base titer at each time p	lpoints e acute respiratory line in SARS-CoV-2 viral oint			
Objectives         Primary         Common to participants with mild/moderate syndrome coronavirus 2 (SARS-CoV-2) inference of the syndrome coronaviru	e and with asymptomatic severe ection <sup>a</sup> lay nts Change from basel titer at each time p	Ipoints e acute respiratory line in SARS-CoV-2 viral oint			
Objectives           Primary           Common to participants with mild/moderate syndrome coronavirus 2 (SARS-CoV-2) infe           • To investigate the antiviral effect of 5-d administration of S-217622 in participate with SARS-CoV-2 infection.           Secondary           Common to participants with mild/moderate administration of S-217622 in participate with SARS-CoV-2 infection.	e and with asymptomatic severa ection <sup>a</sup> lay nts Change from basel titer at each time p	Ipoints         e acute respiratory         line in SARS-CoV-2 viral oint         G-CoV-2 infection <sup>a</sup>			
Objectives           Primary           Common to participants with mild/moderate syndrome coronavirus 2 (SARS-CoV-2) infection           • To investigate the antiviral effect of 5-cd administration of S-217622 in participate with SARS-CoV-2 infection.           Secondary           Common to participants with mild/moderate           • To investigate the antiviral effect of 5-cd administration of S-217622 other than to	e and with asymptomatic severation <sup>a</sup> lay nts Change from base titer at each time p e and with asymptomatic SARS lay he The following end CoV-2 viral titer	Ipoints         e acute respiratory         line in SARS-CoV-2 viral oint         oint         G-CoV-2 infection <sup>a</sup> points concerning SARS-			
Objectives           Primary           Common to participants with mild/moderate syndrome coronavirus 2 (SARS-CoV-2) infe- one           • To investigate the antiviral effect of 5-d administration of S-217622 in participant with SARS-CoV-2 infection.           Secondary           Common to participants with mild/moderate administration of S-217622 other than to primary endpoint in participants with SARS-CoV-2 infection.	e and with asymptomatic severa ection <sup>a</sup> lay nts Change from basel titer at each time p e and with asymptomatic SARS lay he CoV-2 viral titer – Time to the first viral titer	Ipoints         e acute respiratory         line in SARS-CoV-2 viral oint         oint         S-CoV-2 infection <sup>a</sup> points concerning SARS-         r negative SARS-CoV-2			
Objectives         Primary         Common to participants with mild/moderate syndrome coronavirus 2 (SARS-CoV-2) infection         • To investigate the antiviral effect of 5-d administration of S-217622 in participate with SARS-CoV-2 infection.         Secondary         Common to participants with mild/moderate         • To investigate the antiviral effect of 5-d administration of S-217622 in participants with mild/moderate         • To investigate the antiviral effect of 5-d administration of S-217622 other than the primary endpoint in participants with SARS-CoV-2 infection.	e and with asymptomatic severation <sup>a</sup> lay nts e and with asymptomatic from basely titer at each time p e and with asymptomatic SARS lay he CoV-2 viral titer - Time to the first viral titer - Time to negative titers at 2 consed	Ipoints         e acute respiratory         line in SARS-CoV-2 viral oint         oint         S-CoV-2 infection <sup>a</sup> points concerning SARS-         r negative SARS-CoV-2         e SARS-CoV-2 viral cutive time points			
Objectives         Primary         Common to participants with mild/moderate syndrome coronavirus 2 (SARS-CoV-2) infection         • To investigate the antiviral effect of 5-d administration of S-217622 in participate with SARS-CoV-2 infection.         Secondary         Common to participants with mild/moderate         • To investigate the antiviral effect of 5-d administration of S-217622 other than to participants with mild/moderate         • To investigate the antiviral effect of 5-d administration of S-217622 other than to primary endpoint in participants with SARS-CoV-2 infection.	e and with asymptomatic severa ection <sup>a</sup> lay nts Change from basel titer at each time p e and with asymptomatic SARS lay he The following end CoV-2 viral titer – Time to the first viral titer – Time to negative titers at 2 consec – Time to sustaine viral titer	Ipoints         e acute respiratory         line in SARS-CoV-2 viral oint         oint         S-CoV-2 infection <sup>a</sup> points concerning SARS-         r negative SARS-CoV-2         e SARS-CoV-2 viral cutive time points         cutive time points         ed negative SARS-CoV-2			
Objectives           Primary           Common to participants with mild/moderate syndrome coronavirus 2 (SARS-CoV-2) infection           • To investigate the antiviral effect of 5-d administration of S-217622 in participat with SARS-CoV-2 infection.           Secondary           Common to participants with mild/moderate           • To investigate the antiviral effect of 5-d administration of S-217622 in participants with mild/moderate           • To investigate the antiviral effect of 5-d administration of S-217622 other than t primary endpoint in participants with SARS-CoV-2 infection.	e and with asymptomatic severe ection <sup>a</sup> lay nts Change from basel titer at each time p e and with asymptomatic SARS lay he The following end CoV-2 viral titer – Time to the first viral titer – Time to negative titers at 2 consec – Time to sustaine viral titer – Proportion of pa SARS-CoV-2 v	Ipoints         e acute respiratory         line in SARS-CoV-2 viral oint         oint         B-CoV-2 infection <sup>a</sup> points concerning SARS-         e negative SARS-CoV-2         e SARS-CoV-2 viral cutive time points         cd negative SARS-CoV-2         enticipants with positive iral titer at each time point			
Objectives           Primary           Common to participants with mild/moderate syndrome coronavirus 2 (SARS-CoV-2) infe           • To investigate the antiviral effect of 5-d administration of S-217622 in participa with SARS-CoV-2 infection.           Secondary           Common to participants with mild/moderate           • To investigate the antiviral effect of 5-d administration of S-217622 other than the primary endpoint in participants with SARS-CoV-2 infection.	e and with asymptomatic severa ection <sup>a</sup> lay nts Change from basel titer at each time p e and with asymptomatic SARS lay he The following end CoV-2 viral titer – Time to the first viral titer – Time to negative titers at 2 consec – Time to sustaine viral titer – Proportion of pa SARS-CoV-2 viral	Ipoints         e acute respiratory         line in SARS-CoV-2 viral oint         oint         3-CoV-2 infection <sup>a</sup> points concerning SARS-         r negative SARS-CoV-2         e SARS-CoV-2 viral cutive time points         cd negative SARS-CoV-2         articipants with positive iral titer at each time point iral titer at each time point			

Sponsor:	Indi	vidual Study	(For National
Shionogi & Co., Ltd.	Table Referring to Part of		Authority Use only)
Shionogi B.V.	the Dossier		
Name of Finished Product	Volu	ume:	:
Not applicable			
Name of Active Ingredient:	Page	e:	
S-217622			
		<ul> <li>Area under the organization of the second sec</li></ul>	curve (AUC) of change in iral titer
		<ul> <li>The following end transcription polyn (RT-PCR) testing</li> <li>Time to the first</li> </ul>	points concerning reverse nerase chain reaction (nasopharyngeal swabs)
		<ul> <li>Time to the first negative RT-PCR result</li> <li>Time to negative RT-PCR results at 2 consecutive time points</li> </ul>	
		<ul> <li>Time to sustained negative RT-PCR results</li> </ul>	
		<ul> <li>Proportion of participants with positive RT-PCR result at each time point</li> </ul>	
		<ul> <li>Amount of SARS-CoV-2 viral RNA at each time point</li> </ul>	
		<ul> <li>Change from ba SARS-CoV-2 v point</li> </ul>	seline in the amount of iral RNA at each time
		<ul> <li>Relative change amount of SAR each time point</li> </ul>	e rate from baseline in the S-CoV-2 viral RNA at
		<ul> <li>AUC of change CoV-2 viral RN</li> </ul>	in the amount of SARS- A
• To investigate the effect in preventing aggravation following 5-day administra of S-217622 in participants with SARS CoV-2 infection.	ation 5-	<ul> <li>Proportion of part following or highe Ordinal Scale and dose of study inter</li> </ul>	icipants with the er scores on the 8-Point the time from the first evention to reach the
		– Symptomatic, n (Score 1)	o limitation of activities
		<ul> <li>Symptomatic, li (Score 2)</li> </ul>	mitation of activities
		<ul> <li>Hospitalized, no (Score 3)</li> </ul>	o oxygen therapy
		<ul> <li>Hospitalized, w (&lt; 5 L/min) (Sc</li> </ul>	ith oxygen therapy ore 4)
		<ul> <li>Hospitalized, w</li> <li>(≥ 5 L/min) (Sc</li> </ul>	ith oxygen therapy ore 5)
		<ul> <li>Hospitalized, w</li> <li>Death (Score 7)</li> </ul>	ith ventilation (Score 6)

Sponsor:	Individu Table	al Study	(For National Authority Use only)
Shionogi & Co., Ltd.	Referring to Part of		Thundruy Ose only)
Smonogi B: V.	the Doss	ier	
Name of Finished Product	Volume		:
Not applicable			
Name of Active Ingredient:	Page:		
S-217622			
• To investigate quality of life (QOL)	•	Saturation of percu at each time point Change from basel	taneous oxygen (SpO <sub>2</sub> )
following 5-day administration of S-21 in participants with SARS-CoV-2 infec	7622 tion.	5 dimensions 5-lev	el (EQ-5D-5L)
<ul> <li>To confirm the pharmacokinetics (PK) following 5-day administration of S-21 in participants with SARS-CoV-2 infec</li> </ul>	• 7622 tion.	Plasma concentrati (Days 2, 6)	on of S-217622
• To investigate the safety and tolerability following 5-day administration of S-21 in participants with SARS-CoV-2 infec	y 7622 tion.	Adverse events (Al vital signs (systolic pulse rate, respirato electrocardiography	Es), laboratory tests, and /diastolic blood pressure, pry rate), y (ECG)
Participants with mild/moderate SARS-CoV	-2 infection	a	
• To investigate the effect in improving clinical symptoms following 5-day		Time to first impro disease 2019 (COV	vement of coronavirus /ID-19) symptoms <sup>b, c</sup>
administration of S-217622 in participa with mild/moderate SARS-CoV-2 infec	nts tion.	Time to first impro symptoms (duration [3 days] or longer) <sup>1</sup>	vement of COVID-19 n of recovery, 72 hours
	•	Time to first impro symptoms (duration [5 days] or longer) <sup>1</sup>	vement of COVID-19 n of recovery, 120 hours
	•	Time to first impro COVID-19 sympto	vement of each m <sup>b, c</sup>
	•	Change from basel COVID-19 sympto	ine in the total score of ms at each time point <sup>b</sup>
	•	Proportion of partic improvement of CO each symptom at each	cipants with DVID-19 symptoms and ach time point <sup>b, c</sup>
	•	Proportion of partie disorder or smell d	cipants with taste isorder at each time point
	•	• Time to resolution of fever (< 37.0°C)	
Participants with asymptomatic SARS-CoV	-2 infection	1	
• To investigate the preventive effect of 5 administration of S-217622 in participa	o-day • nts	Proportion of partie of COVID-19 symp	ptoms <sup>e, f</sup>
with asymptomatic SARS-CoV-2 infec	tion.	Proportion of partic of COVID-19 symp (≥ 37.0°C) <sup>e, f</sup>	cipants with development ptoms with fever
Exploratory			
Common to participants with mild/moderate and with asymptomatic SARS-CoV-2 infection <sup>a</sup>			

<b>Sponsor:</b> Shionogi & Co., Ltd. Shionogi B.V.	Indi Tab Refe the	vidual Study le erring to Part of Dossier	(For National Authority Use only)
Name of Finished Product	Volu	ime:	:
Not applicable			
Name of Active Ingredient:	Page	e:	
<u>S-217622</u>			
<ul> <li>To evaluate immunity in participants w SARS-CoV-2 infection.</li> <li>To evaluate the effect of 5-day administration of S-217622 on aggrava markers in participants with SARS-CoV infection.</li> </ul>	ith tion V-2	<ul> <li>Geometric mean ti neutralizing antibo</li> <li>Change from basel markers<sup>g</sup></li> </ul>	ter for SARS-CoV-2 dy titer (Days 1, 28) line in aggravation
• To investigate the effect on post-acute COVID-19 syndrome following 5-day administration of S-217622 in participa with SARS-CoV-2 infection.	ints	<ul> <li>Proportion of parti COVID-19 syndro</li> </ul>	cipants with post-acute me at each time point

# Phase 2b Part; Participants with Mild/Moderate SARS-CoV-2 Infection

Objectives	Endpoints	
Primary		
• To compare the effect in improving clinical symptoms following 5-day administration of S-217622 with that of placebo in participants with SARS-CoV-2 infection, based on the time-weighted average change in total score of 12 COVID-19 symptoms from initiation of administration (Day 1) up to 120 hours (Day 6).	• Time-weighted average change in total score of 12 COVID-19 symptoms from initiation of administration (Day 1) up to 120 hours (Day 6) <sup>b</sup>	
• To compare the antiviral effect following 5-day administration of S-217622 with that of placebo in participants with SARS- CoV-2 infection, based on the change from baseline on Day 4 in SARS-CoV-2 viral titer.	• Change from baseline on Day 4 in SARS- CoV-2 viral titer	
Secondary		
• To compare the effect in improving clinical symptoms following 5-day administration of S-217622 with that of placebo in participants with SARS-CoV-2 infection.	<ul> <li>Time to first improvement of COVID-19 symptoms<sup>b, c</sup></li> <li>Time to first improvement of COVID-19 symptoms (duration of recovery, 72 hours [3 days] or longer)<sup>b, c, d</sup></li> <li>Time to first improvement of COVID-19 symptoms (duration of recovery, 120 hours [5 days] or longer)<sup>b, c, d</sup></li> <li>Time to first improvement of each COVID-19 symptom<sup>b, c</sup></li> </ul>	

Sponsor: Shionogi & Co., Ltd. Shionogi B.V.	Individual Study Table Referring to Part of the Dossier	(For National Authority Use only)
Name of Finished Product	voiume:	:
Name of Active Ingredient: S-217622	Page:	
• To compare the antiviral effect of 5-dat administration of S-217622 with that of placebo in participants with SARS-Cov infection.	<ul> <li>Change from base COVID-19 sympt</li> <li>Proportion of part improvement of C each symptom at a Proportion of part disorder or smell a point</li> <li>Time to resolution</li> <li>The following end SARS-CoV-2 vira</li> <li>Time to the first viral titer</li> <li>Time to negative titers at 2 consect</li> <li>Time to sustained viral titer</li> <li>Proportion of part SARS-CoV-2 vira</li> <li>SARS-CoV-2 vira</li> <li>Change from bas viral titer at each</li> <li>Relative change SARS-CoV-2 vira</li> <li>AUC of change titer</li> <li>Time to negative consecutive titer</li> <li>Time to negative titer</li> <li>AUC of change titer</li> <li>Time to the first</li> <li>Time to negative 2 consecutive titer</li> <li>Time to sustained results</li> <li>Proportion of part RT-PCR result a</li> <li>Amount of SAR each time point</li> </ul>	eline in total score of coms at each time point <sup>b</sup> icipants with COVID-19 symptoms and each time point <sup>b, c</sup> icipants with taste disorder at each time n of fever (< 37.0°C) points concerning l titer negative SARS-CoV-2 e SARS-CoV-2 viral cutive time points ed negative SARS-CoV-2 articipants with positive iral titer at each time point iral titer at each time point seline in SARS-CoV-2 n time point rate from baseline in iral titer at each time point in SARS-CoV-2 viral points concerning asopharyngeal swabs) negative RT-PCR result e RT-PCR results at me points ed negative RT-PCR

<b>Sponsor:</b> Shionogi & Co., Ltd. Shionogi B.V.	Indi Tab Refe the I	vidual Study le erring to Part of Dossier	(For National Authority Use only)
Name of Finished Product	Volu	ume:	:
Not applicable			
Name of Active Ingredient:	Page	e:	
S-217622			
• To compare the effect to prevent aggravation following 5-day admini of S-217622 with that of placebo in participants with SARS-CoV-2 infe	istration	<ul> <li>Change from by SARS-CoV-2 v point</li> <li>Relative change amount of SAR each time point</li> <li>AUC of change CoV-2 viral RN</li> <li>Proportion of part following or high Ordinal Scale and dose of study inte scores</li> <li>Symptomatic, n (Score 1)</li> <li>Symptomatic, n (Score 2)</li> <li>Hospitalized, n (Score 3)</li> <li>Hospitalized, w (&lt; 5 L/min) (Sc Hospitalized, w</li> <li>Compatibility (Score 7)</li> <li>Hospitalized, w</li> <li>Death (Score 7)</li> </ul>	aseline in the amount of viral RNA at each time e rate from baseline in the RS-CoV-2 viral RNA at the amount of SARS- NA ticipants with the er scores on the 8-Point the time from the first rvention to reach the no limitation of activities imitation of activities i o oxygen therapy vith oxygen therapy core 4) vith oxygen therapy core 5) vith ventilation (Score 6) ) e point
• To compare QOL following 5-day administration of S-217622 with that placebo in participants with SARS- infection.	at of CoV-2	Change from base	eline in EQ-5D-5L
• To confirm the PK following 5-day administration of S-217622 in partic with SARS-CoV-2 infection.	cipants	• S-217622: Plasma	a concentration (Days 2, 6)
• To compare the safety and tolerability following 5-day administration of S with those of placebo in participants SARS-CoV-2 infection.	ity -217622 s with	• AEs, laboratory to (systolic/diastolic and respiratory ra	ests, and vital signs blood pressure, pulse rate, te)
Exploratory			
• To analyse SARS-CoV-2 lineage fo participants with SARS-CoV-2 infe	or ection.	• Spike gene seque	nce of SARS-CoV-2

Sponsor: Shionogi & Co., Ltd. Shionogi B.V. Name of Finished Product Not applicable	Individual Study Table Referring to Part of the Dossier Volume:		(For National Authority Use only) :
Name of Active Ingredient:	Pag	e:	
S-217622			
• To perform polymorphism analysis of protease (nsp5) for participants with Sz CoV-2 infection.	3CL ARS-	• Gene sequence of 3 SARS-CoV-2	3CL protease (nsp5) of
• To evaluate the amino acid substitution 3CL protease (nsp5) following 5-day administration of S-217622 in participa with SARS-CoV-2 infection.	ns in ants	• Gene sequence of a following study int	3CL protease (nsp5) ervention administration
• To evaluate the antiviral activity of S-217622 against SARS-CoV-2 in participants' specimen.		• Half maximal effect of S-217622 on SA baseline sample	ctive concentration (EC <sub>50</sub> ) RS-CoV-2 isolated from
• To evaluate immunity in participants w SARS-CoV-2 infection.	vith	• Geometric mean tit neutralizing antibo	ter for SARS-CoV-2 dy titer (Days 1, 28)
• To evaluate the effect of 5-day administration of S-217622 on aggrava markers in participants with SARS-Co infection.	tion V-2	<ul> <li>Change from basel markers<sup>g</sup></li> </ul>	ine in aggravation
• To investigate the effect on post-acute COVID-19 syndrome following 5-day administration of S-217622 in participa with SARS-CoV-2 infection.	ants	<ul> <li>Proportion of partic COVID-19 syndrom</li> </ul>	cipants with post-acute me at each time point

# Phase 3 Part, Participants with Mild/Moderate SARS-CoV-2 Infection

Objectives	Endpoints
Primary	
• To compare the effect in improving clinical symptoms following 5-day administration of S-217622 with that of placebo in participants with mild/moderate SARS-CoV-2 infection who have at least 3 moderate symptoms, based on the time to improvement of COVID-19 symptoms.	• Time to first improvement of COVID-19 symptoms <sup>b,c</sup>
Key Secondary	
<ul> <li>To compare the antiviral effect of 5-day administration of S-217622 with that of placebo in participants with SARS-CoV-2 infection, based on time to the first negative SARS-CoV-2 viral titer.</li> </ul>	<ul> <li>Time to the first negative SARS-CoV-2 viral titer</li> <li>Time to first immension of COVID 10</li> </ul>
• To compare the effect in improving clinical symptoms following 5-day administration	• Time to first improvement of COVID-19 symptoms <sup>b,c</sup>

Sponsor	Individual Study	(For National
Shionogi & Co. I td	Table	Authority Use only)
Shionogi B V	Referring to Part of	
Shiohogi B.V.	the Dossier	
Name of Finished Product	Volume:	:
Not applicable		
Name of Active Ingredient:	Page:	
S-217622		
of S-217622 with that of placebo in participants with mild/moderate SARS-CoV-2 infection who have at lea 1 moderate symptoms, based on the tim improvement of COVID-19 symptoms.	ast ne to i	
Other Secondary		
<ul> <li>To compare the effect in improving clir symptoms following 5-day administrati of S-217622 with that of placebo in participants with SARS-CoV-2 infectio</li> <li>To compare the antiviral effect of 5-day administration of S-217622 with that of placebo in participants with SARS-CoV infection.</li> </ul>	<ul> <li>Time to first imp symptoms (durat [3 days] or longe</li> <li>Time to first imp symptoms (durat [5 days] or longe</li> <li>Time to first imp COVID-19 symp</li> <li>Time-weighted a score of 12 COV initiation of adm 120 hours (Day 6</li> <li>Change from bass COVID-19 symp</li> <li>Proportion of part improvement of each symptom at</li> <li>Proportion of part disorder or smell</li> <li>Time to resolution</li> <li>The following er SARS-CoV-2 viral – Time to sust CoV-2 viral – Proportion of part iters at 2 co</li> <li>Time to sust CoV-2 viral – Proportion of part iters at 2 co</li> <li>Time to sust CoV-2 viral – Change from yiral titer at</li> </ul>	rovement of COVID-19 ion of recovery, 72 hours r) <sup>b, c, d</sup> rovement of COVID-19 ion of recovery, 120 hours r) <sup>b, c, d</sup> rovement of each otom <sup>b, c</sup> werage change in total ID-19 symptoms from inistration (Day 1) up to 5) <sup>b</sup> seline in total score of otoms at each time point <sup>b</sup> rticipants with COVID-19 symptoms and c each time point <sup>b, c</sup> rticipants with taste disorder at each time point on of fever (< 37.0°C) adpoints concerning ral titer ative SARS-CoV-2 viral nsecutive time points ained negative SARS- titer of participants with positive -2 viral titer at each time h baseline in SARS-CoV-2 each time point

<b>Sponsor:</b> Shionogi & Co., Ltd. Shionogi B.V.	Individual Study Table Referring to Part of the Dession	(For National Authority Use only)
Name of Finished Product	Volume:	:
Name of Active Ingredient: S-217622	Page:	
<ul> <li>To compare the effect to prevent aggravation following 5-day administra of S-217622 with that of placebo in participants with SARS-CoV-2 infection</li> </ul>	-       Relative char         SARS-CoV-2       point         -       AUC of chan         titer       •         •       The following end         RT-PCR testing (f       -         -       Time to the f         result       -         -       Time to nega         2 consecutive       -         -       Time to susta         results       -         -       Proportion of         RT-PCR resu       -         -       Amount of S.         each time poi       -         -       Change from         SARS-CoV-2       point         -       Relative char         the amount o       at each time point         -       Relative char         the amount o       at each time point         -       Relative char         the amount o       at each time point         -       Relative char         the amount o       at each time point         -       Relative char         the amount o       at each time point         -       AUC of chan         SARS-CoV-2       •         •	nge rate from baseline in 2 viral titer at each time age in SARS-CoV-2 viral dpoints concerning nasopharyngeal swabs) irst negative RT-PCR tive RT-PCR results at e time points ined negative RT-PCR f participants with positive alt at each time point ARS-CoV-2 viral RNA at int baseline in the amount of 2 viral RNA at each time nge rate from baseline in f SARS-CoV-2 viral RNA point ge in the amount of 2 viral RNA ticipants with the er scores on the 8-Point time from the first dose ion to reach the scores c, no limitation of activities a limitation of activities no oxygen therapy with oxygen therapy Score 4) with oxygen therapy Score 5)

Sponsor: Shionogi & Co., Ltd. Shionogi B.V.	Individual Study Table Referring to Part of the Dossier	(For National Authority Use only)
Name of Finished Product	Volume:	:
Name of Active Ingredient:	Dagat	
Name of Active Ingredient:	rage:	
<ul> <li>To compare QOL following 5-day administration of S-217622 with that of placebo in participants with SARS-CoV infection.</li> <li>To confirm the PK following 5-day administration of S-217622 in participa with SARS-CoV-2 infection.</li> <li>To compare the safety and tolerability following 5-day administration of S-21 with those of placebo in participants wi SARS-CoV-2 infection.</li> <li>Exploratory</li> </ul>	<ul> <li>Hospitalized, - Death (Score ' SpO<sub>2</sub> at each time</li> <li>Change from basel</li> <li>Change from basel</li> <li>S-217622: Plasma</li> <li>AEs, laboratory tes (systolic/diastolic land respiratory rate</li> </ul>	with ventilation (Score 6) 7) point line in EQ-5D-5L concentration (Days 2, 6) sts, and vital signs blood pressure, pulse rate, e)
To analyse SARS-CoV-2 lineage for	Spike gene sequen	ce of SARS-CoV-2
<ul> <li>participants with SARS-CoV-2 infectio</li> <li>To perform polymorphism analysis of 3 protease (nsp5) for participants with SA CoV-2 infection.</li> </ul>	on. 3CL • Gene sequence of a ARS- SARS-CoV-2	3CL protease (nsp5) of
• To evaluate the amino acid substitution 3CL protease (nsp5) following 5-day administration of S-217622 in participa with SARS-CoV-2 infection	<ul> <li>Gene sequence of a following study internets</li> </ul>	3CL protease (nsp5) tervention administration
<ul> <li>To evaluate the antiviral activity of S-217622 against SARS-CoV-2 in participant's specimen.</li> </ul>	• EC <sub>50</sub> of S-217622 from baseline sam	on SARS-CoV-2 isolated ple
• To evaluate immunity in participants w SARS-CoV-2 infection.	ith • Geometric mean ti neutralizing antibo	ter for SARS-CoV-2 dy titer (Days 1, 28)
• To evaluate the effect of 5-day administration of S-217622 on aggrava markers in participants with SARS-Cov infection.	• Change from basel markers <sup>g</sup> V-2	ine in aggravation
• To investigate the effect on post-acute COVID-19 syndrome following 5-day administration of S-217622 in participa with SARS-CoV-2 infection.	Proportion of parti COVID-19 syndro	cipants with post-acute me at each time point

<b>Sponsor:</b> Shionogi & Co., Ltd. Shionogi B.V.	Indi Tab Refe the l	vidual Study le erring to Part of Dossier	(For National Authority Use only)
Name of Finished Product	Volu	ume:	:
Not applicable	D		
Name of Active Ingredient:	Page	e:	
S-21/622			
Phase 2b/3 Part; Participants with Asy Infection	/mpto	matic/Mild Symptor	ns Only SARS-CoV-2
Objectives		End	points
Primary		I	
<ul> <li>To compare the effect of 5-day administration of S-217622 on preventi development or worsening of symptoms with that of placebo in participants with SARS-CoV-2 infection.</li> </ul>	ng s	<ul> <li>Proportion of parti development/worse symptoms<sup>e, h</sup></li> </ul>	cipants with ening of COVID-19
Key secondary			
• To compare the antiviral effect of 5-day administration of S-217622 with that of placebo in participants with SARS-CoV-2 infection, based on time to the first negative SARS-CoV-2 viral titer.		• Time to the first negative SARS-CoV-2 viral titer	
Other secondary			
• To investigate the preventive effect of 5 administration of S-217622 in participa with asymptomatic SARS-CoV-2 infect	o-day nts tion.	<ul> <li>Proportion of parti of COVID-19 sym</li> <li>Proportion of parti of COVID-19 sym (≥ 37.0°C)<sup>e, f</sup></li> </ul>	cipants with development ptoms <sup>e, f</sup> cipants with development ptoms with fever
• To compare the antiviral effect of 5-day administration of S-217622 with that of placebo in participants with SARS-CoV-2 infection.		<ul> <li>The following endy CoV-2 viral titer         <ul> <li>Time to negativitiers at 2 constituters at 2 constin at 2 constituters at 2 constinate at 2 constat 2 constinate</li></ul></li></ul>	points concerning SARS- ive SARS-CoV-2 viral secutive time points ned negative SARS- ter participants with positive viral titer at each time viral titer at each time paseline in SARS-CoV-2 uch time point ge rate from baseline in viral titer at each time

<b>Sponsor:</b> Shionogi & Co., Ltd. Shionogi B.V.	Individual Study Table Referring to Part of the Dossier	(For National Authority Use only)
Name of Finished Product	Volume:	:
Name of Active Ingredient:	Page:	
To compare the effect to prevent aggravation following 5-day administra of S-217622 with that of placebo in participants with SARS-CoV-2 infection	-AUC of ch titer•The following of RT-PCR testing - Time to the result-Time to the result-Time to ne 2 consecut-Time to ne 2 consecut-Time to su results-Proportion RT-PCR re ach time p-Amount of each time p-Change fro SARS-CoV point-Relative ch the amount at each time p-AUC of ch SARS-CoVpointRelative cl the amount at each time ordinal Scale a of study interver (Score 1)-Symptoma (Score 1)-Symptoma (Score 3)-Hospitalized (Score 3)-Hospitalized (Score 3)-Hospitalized 	ange in SARS-CoV-2 viral endpoints concerning g (nasopharyngeal swabs) e first negative RT-PCR gative RT-PCR results at ive time points stained negative RT-PCR of participants with positive esult at each time point SARS-CoV-2 viral RNA at coint om baseline in the amount of V-2 viral RNA at each time hange rate from baseline in t of SARS-CoV-2 viral RNA e point ange in the amount of V-2 viral RNA articipants with the gher scores on the 8-Point nd time from the first dose ention to reach the scores tic, no limitation of activities tic, limitation of activities ed, no oxygen therapy ) (Score 4) ed, with oxygen therapy ) (Score 5) ed, with ventilation (Score 6) ore 7) me point

Spansor	Individual Study	(For National	
	Table	(F 0F National Authority Use only)	
Shionogi & Co., Ltd.		Aunoruy Ose oniy)	
Shionogi B.V.	the Dossier		
Name of Finished Product	Volume:	:	
Not applicable			
Name of Active Ingredient:	Page:		
S-217622			
<ul> <li>To compare QOL following 5-day administration of S-217622 with that of placebo in participants with SARS-Co infection.</li> <li>To confirm the PK following 5-day administration of S-217622 in particip with SARS-CoV-2 infection.</li> <li>To compare the safety and tolerability following 5-day administration of S-2</li> </ul>	<ul> <li>Change from bas</li> <li>V-2</li> <li>S-217622: Plasmants</li> <li>AEs, laboratory to (systolic/diastolic)</li> </ul>	tests, and vital signs c blood pressure, pulse rate,	
with those of placebo in participants w SARS-CoV-2 infection.	and respiratory r	ate)	
Exploratory			
• To analyse SARS-CoV-2 lineage for	• Spike gene seque	• Spike gene sequence of SARS-CoV-2	
<ul> <li>To perform polymorphism analysis of protease (nsp5) for participants with S CoV-2 infection.</li> </ul>	3CL     • Gene sequence of SARS-CoV-2	• Gene sequence of 3CL protease (nsp5) of SARS-CoV-2	
• To evaluate the amino acid substitutio 3CL protease (nsp5) following 5-day administration of S-217622 in particip with SARS-CoV-2 infection.	ns in • Gene sequence o following study i ants	f 3CL protease (nsp5) intervention administration	
• To evaluate the antiviral activity of S- 217622 against SARS-CoV-2 in participant's specimen.	• EC <sub>50</sub> of S-21762 from baseline sam	2 on SARS-CoV-2 isolated mple	
• To evaluate immunity in participants v SARS-CoV-2 infection.	with • Geometric mean neutralizing antil	titer for SARS-CoV-2 body titer (Days 1, 28)	
• To evaluate the effect of 5-day administration of S-217622 on aggrav markers in participants with SARS-Co infection.	• Change from bas markers <sup>g</sup> VV-2	eline in aggravation	
• To investigate the effect on post-acute COVID-19 syndrome following 5-day administration of S-217622 in particip with SARS-CoV-2 infection.	Proportion of par COVID-19 synd	rticipants with post-acute rome at each time point	
a Participants with mild/moderate SARS-CoV-2 infection were defined as participants who met inclusion criterion #2 to #4 in Section 9.3.1.1 but did not meet exclusion criterion #1 to #5 in Section 9.3.2.1; participants with asymptomatic SARS-CoV-2 infection were defined as participants who met inclusion criterion #2 and #3 in Section 9.3.1.2 but did not meet exclusion criterion #1 to #5 in Section 9.3.2.2.			
b The following 12 symptoms were evaluated: low energy or tiredness, muscle or body aches, headache, chills or shivering, feeling hot or feverish, stuffy or runny nose, sore throat, cough, shortness of breath (difficulty			

Sp	oonsor:	Individual Study	(For National	
Sh	iionogi & Co., Ltd.	Table	Authority Use only)	
Sh	iionogi B.V.	<b>Referring to Part of</b> the Dossier		
Na	Name of Finished Product Volume: :			
No	ot applicable			
Na	Name of Active Ingredient: Page:			
S-2	217622			
	breathing), nausea, vomiting, and diarrhea.			
с	c The 12 symptoms of COVID-19 were evaluated on a 4-point scale of 0 to 3 (0, None; 1, Mild; 2, Moderate; 3, Severe). The time to improvement of COVID-19 symptoms was defined as the time from the start of study intervention to when all of the symptoms met the following criteria.			
	<ul> <li>Pre-existing symptoms that were presen have worsened at baseline (pre-treatmen moderate or better, or moderate sympton</li> </ul>	t prior to COVID-19 onset and cor tt examination): Severe symptoms ns at baseline has improved to mil	nsidered by the participant to at baseline has improved to d or better for 24 hours.	
<ul> <li>Pre-existing symptoms that were present prior to COVID-19 onset and considered by the participant not to have worsened at baseline (pre-treatment examination): Severe symptoms at baseline has remained severe or improved, or moderate symptoms at baseline has remained moderate or improved for 24 hours.</li> </ul>			nsidered by the participant not ns at baseline has remained erate or improved for 24 hours.	
	<ul> <li>Symptoms other than the above (Sympto after baseline [pre-treatment examinatio</li> </ul>	oms that had not occurred before C n]): Mild or better condition has re	COVID-19 onset, occurred emained for 24 hours.	
d	As for the definition of the time to improvement of COVID-19 symptoms described in c, the duration of improvement read as 72 hours or longer, or 120 hours or longer.			
e	e A total of 14 symptoms were evaluated: taste disorder and smell disorder were added to the 12 symptoms, ie, low energy or tiredness, muscle or body aches, headache, chills or shivering, feeling hot or feverish, stuffy or runny nose, sore throat, cough, shortness of breath (difficulty breathing), nausea, vomiting, and diarrhea.			
f	f Of the 14 symptoms in COVID-19, taste disorder and smell disorder were evaluated on a 3-point scale of 0 to 2 (0, The same as usual; 1, Less than usual; 2, No sense of smell/taste). The other 12 symptoms were evaluated on a 4-point scale of 0 to 3 (0, None; 1, Mild; 2, Moderate; 3, Severe). Participants with development of any COVID-19 symptoms were defined as participants who had symptoms meeting any of the following criteria.			
	<ul> <li>The scores for taste disorder or smell disorder have worsened from 0 (The same as usual) to 1 (Less than usual) or 2 (No sense of smell/taste).</li> </ul>			
	<ul> <li>Feeling hot or feverish, cough, or shortness of breath (difficulty breathing): Severity of none at baseline has worsened to mild or worse, mild symptoms at baseline has worsened to moderate or worse, or moderate symptoms at baseline has worsened to severe on any of the symptoms (severe symptoms at baseline were excluded from the onset judgement of COVID-19 symptoms).</li> </ul>			
	Low energy or tiredness, muscle or body aches, headache, chills or shivering, stuffy or runny nose, sore throat, nausea, vomiting, or diarrhea: Severity of none at baseline has worsened to mild or worse, mild symptoms at baseline has worsened to moderate or worse, or moderate symptoms at baseline has worsened to severe on 2 or more symptoms at the same point (severe symptoms at baseline were excluded from the onset judgement of COVID-19 symptoms).			
g	g Aggravation markers included platelet count, hemoglobin, white blood cell count, lymphocyte count, ALT, LDH, albumin, CRP, CK, PT-INR, IL-6, IFN-λ3, TARC (CCL17), D-dimer, procalcitonin, and KL-6.			
h	<ul> <li>h Of the 14 symptoms in COVID-19, taste disorder and smell disorder are evaluated on a 3-point scale of 0 to 2 (0, The same as usual; 1, Less than usual; 2, No sense of smell/taste). The other 12 symptoms are evaluated on a 4-point scale of 0 to 3 (0, None; 1, Mild; 2, Moderate; 3, Severe). Participants with development/worsening of any COVID-19 symptoms are defined as participants who had symptoms meeting any of the following criteria.</li> </ul>			
	<ul> <li>The scores for taste disorder or smell dis or 2 (No sense of smell/taste), or from 1</li> </ul>	sorder worsen from 0 (The same as (Less than usual) to 2 (No sense o	s usual) to 1 (Less than usual) f smell/taste) (the baseline	

<b>Sponsor:</b> Shionogi & Co., Ltd.	Individual Study Table	(For National Authority Use only)
Shionogi B.V.	<b>Referring to Part of the Dossier</b>	
Name of Finished Product	Volume:	:
Not applicable		
Name of Active Ingredient:	Page:	
S-217622		
score of 2 [No sense of smell/taste] was excluded from the onset/worsening judgement of COVID-19 symptoms).		
<ul> <li>Feeling hot or feverish, cough, shortness of breath (difficulty breathing): Severity of none at baseline worsen to mild or worse, mild symptoms at baseline worsen to moderate or worse, or moderate symptoms at baseline worsen to severe on either symptom (severe symptoms at baseline were excluded from the onset/worsening judgement of COVID-19 symptoms).</li> </ul>		
<ul> <li>Low energy or tiredness, muscle or body aches, headache, chills or shivering, stuffy or runny nose, sore throat, nausea, vomiting, and diarrhea: Severity of none at baseline worsens to mild or worse, mild symptoms at baseline worsen to moderate or worse, or moderate symptoms at baseline worsen to severe which were maintained for 24 hours on 2 or more symptoms at the same point (severe symptoms at baseline were excluded from the onset/worsening judgement of COVID-19 symptoms).</li> </ul>		
i Participants who have one or two moderate (COVID-19 score: 2) symptoms may have been included according to the master protocol.		

#### **Methodology:**

This study consisted of four parts: Phase 2a Part enrolling participants with mild/moderate or asymptomatic SARS-CoV-2 infection, Phase 2b Part and Phase 3 Part enrolling participants with mild/moderate SARS-CoV-2 infection (cohort A to evaluate time to improvement), and Phase 2b/3 Part enrolling participants with asymptomatic/mild symptoms only SARS-CoV-2 infection (cohort B to evaluate development/worsening). This study was a multicenter, randomized, double-blind, placebo-controlled study. The participants were at home, at accommodation facilities, or in a hospital.

In each part, eligible participants were randomly assigned to S-217622 125 mg group, S-217622 250 mg group, or placebo group.

- S-217622 125 mg group (5-day administration once-daily): As a loading dose, S-217622 375 mg was administrated only at the first study intervention. Thereafter, S-217622 125 mg was administered on Days 2 to 5.
- S-217622 250 mg group (5-day administration once-daily): As a loading dose, S-217622 750 mg was administrated only at the first study intervention. Thereafter, S-217622 250 mg was administered on Days 2 to 5.
- Placebo group Placebo was administered once daily for 5 days.

Each Part consisted of the intervention period (Days 1 to 5), the follow-up period (Days 6 to 28), and the exploratory period (Days 29 to 337), which was common for all Parts. Participants were considered to have completed the study if he/she had

Sponsor:	Individual Study	(For National
Shionogi & Co., Ltd.	Table	Authority Use only)
Shionogi B.V.	<b>Referring to Part of</b>	
0	the Dossier	
Name of Finished Product	Volume:	:
Not applicable		
Name of Active Ingredient:	Page:	
S-217622		

completed the follow-up period. Only participants who agreed to participate in the exploratory period were evaluated in the period.

In this study, the Data and Safety Monitoring Board was established for the purpose of third-party evaluation of safety throughout the study period. The Independent Data Monitoring Committee (IDMC) will be established for the interim analyses of the primary endpoint and the key secondary endpoint of each of Phase 3 Part and Phase 2b/3 Part for the purpose of decision on stopping the study for efficacy reasons. It will control such unblinded information as the key codes and the results of analysis which may have an impact on the conduct or evaluation of Phase 3 Part and Phase 2b/3 Part.

#### Number of Participants (Planned and Analyzed):

#### Planned:

For Phase 2a Part, 69 eligible participants with mild/moderate or asymptomatic SARS-CoV-2 infection were to be enrolled in 3 groups (23 participants/group). The number of participants by condition (mild/moderate or asymptomatic) in each group was not pre-defined.

For Phase 2b Part, 435 eligible participants with mild/moderate SARS-CoV-2 infection who have at least 1 moderate symptom were to be enrolled in 3 groups (145 participants/group).

For Phase 3 Part, 1260 eligible participants with mild/moderate SARS-CoV-2 infection who have at least 3 moderate symptoms will be enrolled in 3 groups (420 participants/group). In the case no interim analysis is performed for the purpose of decision on stopping the study for efficacy reasons, 1215 eligible participants will be randomly assigned to each of these intervention groups (405 participants/group).

For Phase 2b/3 Part, 600 eligible participants with asymptomatic/mild symptoms only SARS-CoV-2 infection will be enrolled in 3 groups (200 participants/group). In the case no interim analysis is performed for the purpose of decision on stopping the study for efficacy reasons, 570 eligible participants will be randomly assigned to each of these intervention groups (190 participants/group).

#### Randomized (Phase 2b Part):

#### Analyzed for efficacy (Phase 2b Part):

Participants with mild/moderate SARS-CoV-2 infection

Intention-to-treat 1 (ITT1) population:
 341 participants (114 in the S-217622 125 mg group, 116 in the S-217622 250 mg group, and 111 in the placebo group)

<b>Sponsor:</b> Shionogi & Co., Ltd.	Individual Study Table	(For National Authority Use only)
Shionogi B.V.	<b>Referring to Part of the Dossier</b>	
Name of Finished Product	Volume:	:
Not applicable		
Name of Active Ingredient:	Page:	
S-217622		
<ul> <li>Analyzed for safety (Phase 2b Part):</li> <li>Safety analysis population 421 participants (140 in the S-217622 125 mg group, 140 in the S-217622 250 mg group, and 141 in the placebo group)</li> </ul>		
<b>Diagnosis and Main Criteria for Inclusion:</b> The inclusion and exclusion criteria were common for all Parts.		

1. Inclusion criteria

Common to participants with mild/moderate, with asymptomatic, and with asymptomatic/mild symptoms only SARS-CoV-2 infection:

- Male and female participants who were 12 to < 70 years of age, at the time of signing the informed consent/assent.
- Participants who were diagnosed as SARS-CoV-2 positive within 120 hours before randomization.
- Participants under 20 years of age at the time of assent had to weigh  $\ge 40$  kg.

Participants with mild/moderate SARS-CoV-2 infection only (Phase 2a Part, Phase 2b Part, and Phase 3 Part):

- Participants with a time from COVID-19 onset (when at least one of 14 symptoms of COVID-19 occurred) to randomization of ≤ 120 hours.
- Participants who had at least one moderate (COVID-19 score: 2) or severe symptom among the 12 COVID-19 symptoms at randomization (excluding symptoms present prior to COVID-19 onset)

Or participants who had at least one moderate (COVID-19 score: 2) or severe pre-existing symptom (symptoms present prior to COVID-19 onset) which the participants considered to have worsened at baseline:

Participants with asymptomatic SARS-CoV-2 infection only (Phase 2a Part only):

• Participants who had none of the COVID-19 symptoms (except symptoms present before SARS-CoV-2 infection) within 2 weeks before randomization.

Participants with asymptomatic/mild symptoms only SARS-CoV-2 infection (Phase 2b/3 Part only):

• Participants who did not have any symptoms of moderate (COVID-19 symptom score: 2) or severe out of the 12 symptoms due to COVID-19 infection within 2 weeks before randomization (excluding symptoms present prior to COVID-19 onset).

Sponsor:	Individual Study	(For National	
Shionogi & Co., Ltd.	Table	Authority Use only)	
Shionogi B.V.	<b>Referring to Part of the Dossier</b>		
Name of Finished Product	Volume:	:	
Not applicable			
Name of Active Ingredient:	Page:		
S-217622			
2. Exclusion criteria			
• Participants with a SpO <sub>2</sub> of	luring wakefulness of $\leq 93\%$	(room air)	
• Participants who needed of	oxygen administration or a res	spirator	
<ul> <li>Participants who were strongly suspected to have worsening of symptoms of SARS-CoV-2 infection within 48 hours after randomization, in the opinion of the investigator/subinvestigator</li> <li>Participants with suspected active and systemic infections requiring treatment at the time of randomization (excluding SARS-CoV-2)</li> </ul>			
Test Product, Dose and Mode o	f Administration, Lot Num	ber (Phase 2b Part):	
Study Intervention Name F	Packaging Lot No.		
S-217622 tablet 250 mg J	apan:		
S-217622 tablet 125 mg	Day1,		
	Days 2 to 5,		
S	South Korea:		
	Day1,		
	Days 2 to 5,		
S-217622 tablet 250 mg or S-217622 tablet 125 mg was orally administered as			
described in the Methodology.			
<b>Duration of Treatment:</b>			
Once daily for 5 days			

<b>Sponsor:</b> Shionogi & Co., Ltd.	Individual Study Table	(For National Authority Use only)
Shionogi B.V.	<b>Referring to Part of the Dossier</b>	
Name of Finished Product	Volume:	:
Not applicable		
Name of Active Ingredient:	Page:	
8-217622	_	

# Reference Therapy, Dose and Mode of Administration, Lot Number (Phase 2b Part):



S-217622 tablet Placebo-D and/or S-217622 tablet Placebo-B was orally administered as described in the Methodology.

#### **Criteria for Evaluation:**

#### Efficacy Assessment:

1. Virologic Examination

The investigator or his/her designee took nasopharyngeal swab from participants. SARS-CoV-2 virus titer and viral amount of viral RNA were measured, whether the sample was positive or negative was determined by RT-PCR.

2. Participant Diary

Participants assessed their COVID-19 symptom scores and EQ-5D-5L, measured  $SpO_2$  and temperature, and entered the results in the participant diary.

• COVID-19 Symptom Score

Of the 14 COVID-19 symptoms listed below, participants assessed taste disorder and smell disorder themselves using a 3-point scale of 0 to 2 (0, The same as usual; 1, Less than usual; 2, No sense of smell/taste) and the other 12 symptoms using a 4-point scale of 0 to 3 (0, None; 1, Mild; 2, Moderate; 3, Severe) according to the protocol-specified schedule.

- General symptoms: Low energy or tiredness, muscle or body aches, headache, chills or shivering, feeling hot or feverish, taste disorder, smell disorder
- Respiratory symptoms: Stuffy or runny nose, sore throat, cough, and shortness of breath (difficulty breathing)
- Gastrointestinal symptoms: Nausea, vomiting, and diarrhea

<b>Sponsor:</b> Shionogi & Co., Ltd. Shionogi B.V.	Individual Study Table Referring to Part of the Dossier	(For National Authority Use only)
Name of Finished Product	Volume:	:
Not applicable		
Name of Active Ingredient:	Page:	
S-217622		

• SpO<sub>2</sub>

Participants measured SpO<sub>2</sub> using a pulse oximeter according to the protocol-specified schedule.

• Body Temperature

Participants measured axillary temperature according to the protocol-specified schedule.

• EQ-5D-5L

Participants assessed EQ-5D-5L according to the protocol-specified schedule.

EQ-5D-5L questionnaire consists of 2 pages: EQ-5D-5L descriptive questionnaire and EQ Visual Analog Scale (VAS). The descriptive questionnaire assesses 5 parameters (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) on a 5-point scale. The EQ VAS scores assess the participant's current health on a 20 cm visual analogue scale, where the best state is 100 and the worst state is 0.

3. 8-Point Ordinal Scale

The investigator/subinvestigator assessed the participant's condition on the 8-Point Ordinal Scale of 0 to 7 according to the protocol-specified schedule.

The scores on the 8-Point Ordinal Scale are 0) Asymptomatic; 1) Symptomatic, no limitation of activities; 2) Symptomatic, limitation of activities; 3) Hospitalized, no oxygen therapy; 4) Hospitalized, with oxygen therapy ( $\leq 5$  L/min); 5) Hospitalized, with oxygen therapy ( $\geq 5$  L/min); 6) Hospitalized, with ventilation; and 7) Death.

#### **Other Assessments:**

Results of the following assessments will be reported separately from the clinical study report.

- Biomarkers (aggravation markers)
- SARS-CoV-2 lineage
- Polymorphisms of 3CL Protease (nsp5)
- Proportion of amino acid substitution in 3CL protease (nsp5) gene
- Drug antiviral activity
- Immunity (SARS-CoV-2 neutralizing antibody titers)

<b>Sponsor:</b> Shionogi & Co., Ltd. Shionogi B.V.	Individual Study Table Referring to Part of the Dossier	(For National Authority Use only)
Name of Finished Product	Volume:	:
Not applicable		
Name of Active Ingredient:	Page:	
S-217622		

#### Safety Assessment:

Safety was assessed through physical examinations, laboratory tests, vital signs, and ECGs. All AEs/serious AEs (SAEs) were collected from the date of signing of the informed consent form (ICF)/assent through the end of follow-up period. The severity and seriousness of an event was determined by the investigator according to the protocol-specified definitions. The relationship of an event to the study intervention was determined by the investigator.

#### **Pharmacokinetics Assessment:**

For the measurement of plasma S-217622 concentrations, blood samples were collected on Days 2 and 6.

#### **Statistical Methods:**

#### Efficacy Analyses:

In general, efficacy analyses were performed for ITT population (Phase 2a Part), ITT1 population (Phase 2b Part), ITT2 population (Phase 3 Part, Phase 2b/3 Part), or mITT population, ie, ITT or ITT2 participants who had a positive SARS-CoV-2 viral titer at baseline (common for Phase 2a Part, Phase 3 Part, and Phase 2b/3 Part). As for the primary endpoints of Phase 2a Part and Phase 2b Part, and the primary and key secondary endpoints of Phase 3 Part and Phase 2b/3 Part, only the primary analyses were to be performed based on the PPS instead of ITT, ITT1, and ITT2 population, respectively, and based on the PPS with positive SARS-CoV-2 viral titer at baseline instead of mITT population for Phase 2a Part, Phase 3 Part, and Phase 2b/3 Part and ITT1 population for Phase 2b Part.

Primary Endpoint in Phase 2a Part (Participants with Mild/Moderate or Asymptomatic SARS-CoV-2 infection)

The primary endpoint in Phase2a Part, ie, the change from baseline in SARS-CoV-2 viral titer at each time point, was defined as the absolute change from baseline in SARS-CoV-2 viral titer at each time point. Summary statistics for the change from baseline in SARS-CoV-2 viral titer at each time point were calculated using the mITT population for the participants with mild/moderate SARS-CoV-2 infection, the participants with asymptomatic SARS-CoV-2 infection, and the merged population separately. In addition, the van Elteren test was applied to the merged population of mild/moderate and asymptomatic SARS-CoV-2 infection for a pairwise comparison of SARS-CoV-2 viral titer at each time point between each S-217622 treatment group and the placebo group at a two-sided significance level of 0.05. As stratification factors for van Elteren test, the condition of SARS-CoV-2 infection (mild/moderate or

<b>Sponsor:</b> Shionogi & Co., Ltd.	Individual Study Table	(For National Authority Use only)
Shionogi B.V.	Referring to Part of	
	the Dossier	
Name of Finished Product	Volume:	:
Not applicable		
Name of Active Ingredient:	Page:	
S-217622		
asymptomatic) was used. No multiplicity adjustment was performed in these pairwise		
comparisons.		
Drive on Endraint in Diago 2h Dart (Dartisin ante swith Mild/Madante SADS CaV 2		

Primary Endpoint in Phase 2b Part (Participants with Mild/Moderate SARS-CoV-2 Infection)

The primary efficacy endpoints in participants with mild/moderate SARS-CoV-2 infection in Phase 2b Part were the time-weighted average change in total score of 12 COVID-19 symptoms from initiation of administration (Day 1) up to 120 hours (Day 6) and the change from baseline on Day 4 in SARS-CoV-2 viral titer.

As the primary analysis for this primary endpoint, pairwise comparison was performed between each S-217622 intervention group and the placebo group, analysis of covariance was applied with time-weighted average change as response, and by time from COVID-19 onset to randomization (< 72 hours,  $\geq$  72 hours), SARS-CoV-2 vaccination history, and the total score of the 12 symptoms of COVID-19 at baseline as covariates in participants with mild/moderate SARS-CoV-2 infection whose total score of 12 symptoms of COVID-19 was one or higher at the initiation of administration (Day 1) in the ITT1 population. In addition, as the primary analysis for change from baseline on Day 4 in SARS-CoV-2 viral titer, pairwise comparison was performed between each S-217622 intervention group and the placebo group, analysis of covariance was applied with change from baseline on Day 4 in SARS-CoV-2 viral titer as response, and by time from COVID-19 onset to randomization (< 72 hours,  $\geq$  72 hours), SARS-CoV-2 vaccination history, and SARS-CoV-2 viral titer at baseline as covariates in participants with mild/moderate SARS-CoV-2 infection in the ITT1 population. The multiplicity adjustment was performed in these pairwise comparisons by using a fixed-sequence procedure.

Primary Endpoint in Phase 3 Part (Participants with Mild/Moderate SARS-CoV-2 Infection)

The primary endpoint in Phase 3 Part for participants with mild/moderate SARS-CoV-2 infection, ie, the time to improvement of COVID-19 symptoms is defined as the time from the start of the study intervention to improvement of all 12 symptoms of COVID-19 (low energy or tiredness, muscle or body aches, headache, chills or shivering, feeling hot or feverish, stuffy or runny nose, sore throat, cough, shortness of breath [difficulty breathing], nausea, vomiting, and diarrhea). The improvement of symptoms is defined in the footnotes to Objectives and Endpoints.

As the primary analysis for this primary endpoint, a pairwise comparison of the time to improvement of COVID-19 symptoms will be performed between each S-217622 treatment group and the placebo group using a log-rank test stratified by the time from

<b>Sponsor:</b> Shionogi & Co., Ltd.	Individual Study Table	(For National Authority Use only)
Shionogi B.V.	<b>Referring to Part of the Dossier</b>	
Name of Finished Product	Volume:	:
Not applicable		
Name of Active Ingredient:	Page:	

COVID-19 onset to randomization (< 72 hours,  $\geq$  72 hours) and SARS-CoV-2 vaccination history at a one-sided significance level of 0.025 in the participants with mild/moderate SARS-CoV-2 infection population of participants who have at least 3 moderate symptoms in the ITT2 population. In addition, in the mild/moderate SARS-CoV-2 infection population of participants who have at least 1 moderate symptom in the ITT2 population, a similar analysis will be performed as a key secondary analysis. The multiplicity adjustment will be applied to the primary analysis. The following analyses will be performed as other analyses.

- Pairwise comparison using the generalized Wilcoxon test stratified by time from COVID-19 onset to randomization (< 72 hours, ≥ 72 hours) and SARS-CoV-2 vaccination history between each S-217622 treatment group and the placebo group will be performed.
- Kaplan-Meier curves will be plotted for each treatment group and the median time to improvement of COVID-19 symptoms and its 95% confidence interval (CI) will be calculated. Moreover, the difference in median between treatment groups and its 95% CI will be calculated.
- The hazard ratio of each S-217622 treatment group to the placebo group will be estimated using a Cox proportional hazard model stratified by time from COVID-19 onset to randomization (< 72 hours, ≥ 72 hours) and SARS-CoV-2 vaccination history.
- Restricted mean survival time (RMST) with a 21-day investigation period will be estimated for each treatment group and pairwise comparison between each S-217622 treatment group and the placebo group will be performed.

Primary Endpoint in Phase 2b/3 Part (Participants with Asymptomatic/Mild Symptoms Only SARS-CoV-2 Infection)

The primary endpoint in Phase 2b/3 Part for participants with asymptomatic/mild symptoms only SARS-CoV-2 infection, ie, the proportion of participants with development/worsening of COVID-19 symptoms, is defined as the proportion of participants in the asymptomatic/mild symptoms only SARS-CoV-2 infection population in the ITT2 population with development/worsening of any of the 12 symptoms of COVID-19, taste disorder, or smell disorder by 14 days after the first administration of the study intervention. The development/worsening of symptoms is determined according to the protocol-specified rules.

As the primary analysis for this primary endpoint, a pairwise comparison of the proportion of participants with development/worsening of COVID-19 symptoms will be performed between each S-217622 treatment group and the placebo group using

<b>Sponsor:</b> Shionogi & Co., Ltd. Shionogi B.V.	Individual Study Table Referring to Part of the Dossier	(For National Authority Use only)
Name of Finished Product	Volume:	:
Not applicable		
Name of Active Ingredient:	Page:	
S-217622		

the Mantel-Haenszel test stratified by SARS-CoV-2 vaccination history at a one-sided significance level of 0.025 in the participants with asymptomatic/mild symptoms only SARS-CoV-2 infection in the ITT2 population. The multiplicity adjustment will be applied to the primary analysis.

As an additional analysis for this primary endpoint, the risk ratio of each S-217622 treatment group to the placebo group will be estimated.

Key Secondary Endpoint in Phase 3 Part and Phase 2b/3 Part

The key secondary endpoint in Phase 3 Part and Phase 2b/3 Part, ie, the time to the first negative SARS-CoV-2 viral titer, is defined as the time from the start of the study intervention to the first confirmed drop of SARS-CoV-2 viral titer below the detection limit. Participants whose SARS-CoV-2 viral titer was not confirmed to be negative will be handled as censored cases according to the time of the last evaluation of SARS-CoV-2 virus titer or the time of the last evaluation of SARS-CoV-2 virus titer before the first administration of protocol-specified prohibited concomitant drug, whichever is earlier.

The primary analysis for this key secondary endpoint is planned for participants with mild/moderate SARS-CoV-2 infection and those with asymptomatic/mild symptoms only SARS-CoV-2 infection separately. Pairwise comparison of the time to the first negative SARS-CoV-2 viral titer will be performed between each S-217622 treatment group and the placebo group using a log-rank test stratified by the time from COVID-19 onset to randomization (< 72 hours,  $\geq$  72 hours) and SARS-CoV-2 vaccination history at a one-sided significance level of 0.025 in participants with mild/moderate SARS-CoV-2 infection in mITT population of each Phase 3 Part and Phase 2b/3 Part. Pairwise comparison of the time to the first negative SARS-CoV-2 viral titer will be compared between each S-217622 treatment group and the placebo group using a log-rank test stratified by the SARS-CoV-2 vaccination history at a one-sided significance level of 0.025 in participants with asymptomatic/mild symptoms only SARS-CoV-2 infection in the mITT population. The multiplicity adjustment will be applied to the primary analysis.

The following analyses will be performed as additional analyses for the key secondary endpoint. The multiplicity adjustment as planned for the primary analysis will not be performed for statistical tests involving between-group comparisons that will be performed in the following analyses.

 Pairwise comparison will be performed using the generalized Wilcoxon test stratified by the time from COVID-19 onset to randomization (< 72 hours, ≥ 72 hours) and SARS-CoV-2 vaccination history between each S-217622

Sponsor:	Individual Study	(For National	
Shionogi & Co., Ltd.	Table	Authority Use only)	
Shionogi B.V.	Referring to Part of the Dossier		
Name of Finished Product	Volume:	:	
Not applicable			
Name of Active Ingredient:	Page:		
S-217622			
<ul> <li>treatment group and the placebo group in the participants with mild/moderate SARS-CoV-2 infection. Pairwise comparison will be performed using the generalized Wilcoxon test stratified by the SARS-CoV-2 vaccination history between each S-217622 treatment group and the placebo group in the participants with asymptomatic/mild symptoms only SARS-CoV-2 infection.</li> <li>For participants with mild/moderate SARS-CoV-2 infection, Kaplan-Meier curves of each group will be plotted, and the median time to the first negative SARS-CoV-2 viral titer and its 95% CI will be calculated. Moreover, the difference in median between treatment groups and its 95% CI will be calculated.</li> <li>The hazard ratio of each S-217622 treatment group to the placebo group will be estimated using a Cox proportional hazard model stratified by the time from COVID-19 onset to randomization (&lt; 72 hours, ≥ 72 hours) and SARS-CoV-2 infection. The hazard ratio of each S-217622 treatment groups with mild/moderate SARS-CoV-2 vaccination history in the participants with mild/moderate SARS-CoV-2 infection. The hazard ratio of each S-217622 treatment group to the placebo group will be estimated using a Cox proportional hazard model stratified by SARS-CoV-2 vaccination history in the participants with asymptomate SARS-CoV-2 vaccination history in the participants with asymptomate stratified by SARS-CoV-2 vaccination history in the participants with asymptomate stratified by SARS-CoV-2 vaccination history in the participants with asymptomate stratified by SARS-CoV-2 vaccination history in the participants with asymptomate stratified by SARS-CoV-2 vaccination history in the participants with asymptomate stratified by SARS-CoV-2 vaccination history in the participants wit</li></ul>			
• For participants with mild/moderate SARS-CoV-2 infection and those with asymptomatic/mild symptoms only SARS-CoV-2 infection, RMST with a 21-day investigation period will be estimated for each treatment group, and a pairwise comparison between each S-217622 treatment group and the placebo group will be performed.			
Safety Analyses:			
All safety analyses were to be perform Phase 2a Part, Phase 2b Part, Phase 3 combined. In merged Parts, analyses CoV-2 infection population, the asym infection population, and the merged AEs were coded and classified by sys	ned in the safety analysis p Part, and Phase 2b/3 Part, will be performed in the m ptomatic/mild symptoms of population of these popula tem organ class (SOC) and	oopulation for and these parts ild/moderate SARS- only SARS-CoV-2 tions. d preferred term (PT)	
using the Medical Dictionary for Reg number and proportion of participants events (TEAEs), TEAEs with an outc	ulatory Activities (MedDF s who experienced treatme ome of death, serious TEA	A) Version 24.0. The nt-emergent adverse AEs other than deaths,	

Confidential

and TEAE leading to discontinuation of the study intervention were summarized by treatment group. The number and proportion of participants who experienced TEAEs

Sponsor:	Individual Study	(For National
Shionogi & Co., Ltd.	Table	Authority Use only)
Shionogi B.V.	<b>Referring to Part of</b>	
	the Dossier	
Name of Finished Product	Volume:	:
Not applicable		
Name of Active Ingredient:	Page:	
\$ 217622		

in each category of severity and outcome were summarized by SOC and PT for each Part. Treatment-related TEAEs were summarized in the same manner as TEAEs.

For laboratory test values and vital signs, summary statistics of measurement values and their changes from baseline were calculated by treatment group for each scheduled time point. Qualitative laboratory data were summarized by the numbers of participants in the test categories at baseline and scheduled time points using shift tables.

For ECGs (Phase 2a Part only), summary statistics for ECG interpretations (normal, abnormal but not clinically significant, or abnormal and clinically significant) at each scheduled time point after randomization (including baseline) were calculated for each treatment group.

#### **PK Analyses:**

For the PK concentration population, plasma S-217622 concentrations were listed for each treatment group and Day along with the time elapsed from the last dosing of study intervention prior to blood sampling each for Phase 2a Part, Phase 2b Part, Phase 3 Part and Phase 2b/3 Part. Plasma trough concentrations (C<sub>24</sub>) defined as plasma S-217622 concentrations within 20 to 28 hours after the first dose on Day 2 were summarized by treatment group and part with N, mean (Mean), standard deviation (SD), coefficient of variation (CV%, calculated as SD/mean × 100), geometric mean and its coefficient of variation (CV% geometric mean, calculated as  $\{\exp [sd^2] - 1\}^{1/2} \times 100$ , where sd was the SD of natural log-transformed values), median (Median), minimum (Min), and maximum (Max) each for Phase 2a Part, Phase 2b Part, Phase 3 Part and Phase 2b/3 Part. If possible, C<sub>24</sub> were summarized by age group (12 to18 years old, 19 to 64 years old, and over 65 years old). The data were not to be summarized for a group with N less than 3. The plasma concentrations of S-217622 versus the time from the last dosing of study intervention prior to blood sampling were graphically presented at the linear scale by treatment group.

<b>Sponsor:</b> Shionogi & Co., Ltd. Shionogi B.V.	Individual Study Table Referring to Part of the Dossier	(For National Authority Use only)
Name of Finished Product	Volume:	:
Not applicable		
Name of Active Ingredient:	Page:	
S-217622		

#### Summary of Results:

### Efficacy (Phase 2b Part):

The primary objective of Phase 2b Part is to evaluate the improvement of clinical symptoms up to Day 6 and the antiviral effect against SARS-CoV-2 on Day 4 in participants with mild/moderate SARS-CoV-2 infection. In Phase 2b Part, unblinding was performed when the observation on Day 6 had been completed in the last participant of Phase 2b Part, and the efficacy of S-217622 was evaluated with co-primary endpoints (time-weighted average change in total score of the 12 COVID-19 symptoms from initiation of administration [Day 1] up to 120 hours [Day 6] and the change from baseline on Day 4 in SARS-CoV-2 viral titer) based on the results collected up to Day 6 of all participants. Efficacy and safety data continued to be collected through Day 7 and thereafter, and an exploratory evaluation of the efficacy was performed when the observation on Day 21 had been completed in all participants. In this CSR, the efficacy up to the unblinding is mainly described but the data collected after the unblinding are also included.

The results up to the unblinding are summarized below.

Data Sets Analyzed

- A total of 428 participants with mild/moderate SARS-CoV 2 infection were randomized to one of the treatment groups.
- The ITT1 population consisted of 341 participants (114 in the S-217622 125 mg group, 116 in the S-217622 250 mg group, and 111 in the placebo group).

#### Demographics and Other Baseline Characteristics

For participants in the ITT1 population:

The proportion of male participants was greater in the placebo group than in either of the S-217622 treatment groups; male participants accounted for 53.5% (61/114) in the S-217622 125 mg group, 56.9% (66/116) in the S-217622 250 mg group, and 64.9% (72/111) in the placebo group (hereafter in the same order). The median age (range) was 32.0 years (14–68), 34.0 years (12–69), and 37.0 years (16–68), respectively; the age was comparable across the treatment groups. Participants under 20 years and over 65 years of age were enrolled in each treatment group. All participants except for 1 each in the S-217622 250 mg and placebo groups were Asian (339/341), most of whom were Japanese (335/339). The time from disease onset to enrollment was ≥ 72 hours in approximately half of participants in all treatment groups: 51.8%

<b>Sponsor:</b> Shionogi & Co., Ltd. Shionogi B.V.	Individual Study Table Referring to Part of the Dossier	(For National Authority Use only)
Name of Finished Product	Volume:	:
Not applicable		
Name of Active Ingredient:	Page:	
S-217622		

(59/114), 54.3% (63/116), and 51.4% (57/111), respectively. A great majority of participants had received COVID-19 vaccination in all treatment groups: 85.1% (97/114), 83.6% (97/116), and 87.4% (97/111), respectively.

#### Primary Endpoint

For participants in the ITT1 population:

- The time-weighted average change in total score of the 12 COVID-19 symptoms from initiation of administration (Day 1) up to 120 hours (Day 6) (SD) was -5.95 (4.02) in the S-217622 125 mg group and -4.92 (3.25) in the placebo group, and there was no statistically significant difference between the S-217622 125 mg group and the placebo group. However, the least squares (LS) means of the time-weighted average changes were greater in the S-217622 125 mg group than in the placebo group. The mean (SD) change from baseline in SARS-CoV-2 viral titer on Day 4 (log<sub>10</sub> [TCID<sub>50</sub>/mL]) was -1.69 (0.84) in the S-217622 125 mg group and -1.06 (0.99) in the placebo group. The LS means of the change from baseline in SARS-CoV-2 viral titer on Day 4 showed a statistically significantly greater decrease by 0.41 log<sub>10</sub> (TCID<sub>50</sub>/mL) in the S-217622 125 mg group compared with the placebo group (p < 0.0001).
- In the comparison in the co-primary endpoints between S-217622 125 mg group and the placebo group, one of these endpoints failed to show a statistically significant difference. Therefore, in the context of the fixedsequence procedure for multiplicity adjustment, it has been interpreted that the co-primary endpoints also failed to show a statistical significance in the comparison between S-217622 250 mg group and the placebo group. The following results of comparisons in the co-primary endpoints between S-217622 250 mg group and the placebo group should be interpreted as secondary analyses. The time-weighted average change in total score of the 12 COVID-19 symptoms from initiation of administration (Day 1) up to 120 hours (Day 6) (SD) was -5.42 (3.70) in the S-217622 250 mg group and -4.92 (3.25) in the placebo group, and there was no statistically significant difference between the S-217622 250 mg group and the placebo group. However, the LS means of the time-weighted average changes were greater in the S-217622 250 mg group than in the placebo group. The mean (SD) change from baseline in SARS-CoV-2 viral titer on Day 4 (log<sub>10</sub> [TCID<sub>50</sub>/mL]) was -1.43 (0.83) in the S-217622 250 mg group and -1.06 (0.99) in the placebo group. The LS means of the change from baseline in SARS-CoV-2 viral titer

<b>Sponsor:</b> Shionogi & Co., Ltd. Shionogi B.V.	Individual Study Table Referring to Part of	(For National Authority Use only)
Name of Finished Product	the Dossier Volume:	:
Not applicable		
Name of Active Ingredient:	Page:	
S-217622		

on Day 4 showed a statistically significantly greater decrease by 0.4  $log_{10}$  (TCID<sub>50</sub>/mL) in the S-217622 250 mg group compared with the placebo group (p < 0.0001).

Secondary Endpoints

For participants in the ITT1 population:

- The 12 COVID-19 symptoms were categorized into the following 5 symptom subsets: acute symptoms (sore throat, cough, and feeling hot or feverish); main clinical symptoms (stuffy or runny nose, sore throat, cough, chills or shivering, and feeling hot or feverish); respiratory symptoms (stuffy or runny nose, sore throat, cough, and shortness of breath [difficulty breathing]); systemic symptoms (low energy or tiredness, muscle or body aches, headache, chills or shivering, and feeling hot or feverish); and gastrointestinal symptoms (nausea, vomiting, or diarrhoea). The time-weighted average changes were analyzed for the subtotal of symptom scores for each of the 5 symptom subsets from initiation of administration (Day 1) up to 120 hours (Day 6). The respiratory symptoms showed a significant improvement in either the S-217622 125 mg or 250 mg group compared with the placebo group (p = 0.0153 and p = 0.0033, respectively). The main clinical symptoms and acute symptoms were significantly improved in the S-217622 250 mg group compared with the placebo group (p = 0.0149 for the main clinical symptoms and p = 0.0070 for the acute symptoms), while they tended to be improved in the S-217622 125 mg group compared with the placebo group without a significant difference. Compared to these symptom groups, the systemic symptoms or the gastrointestinal symptoms did not show a significant difference between either of the S-217622 treatment groups and the placebo group. Although the LS mean of the changes in the systemic symptoms did not show a significant difference between either of the S-217622 treatment groups and the placebo group, a decrease in symptom scores was observed over time. The gastrointestinal symptoms did not produce sufficient symptoms at the baseline to evaluate the difference between each of the S-217622 treatment groups and the placebo group.
- The changes from baseline in total score of the 12 COVID-19 symptoms (SD) 12 hours post-dose were -3.4 (3.9) in the S-217622 125 mg group, -2.6 (3.2) in the S-217622 250 mg group, and -2.6 (3.3) in the placebo group (hereafter in the same order), -4.5 (4.1), -3.8 (3.8), and -3.5 (3.5) 24 hours post-dose, -6.0 (4.8), -5.7 (4.3), and -4.7 (3.6) 48 hours post-dose, -6.7 (4.3), -6.8

Sponsor:	Individual Study	(For National
Shionogi & Co., Ltd.	Table	Authority Use only)
Shionogi B.V.	Referring to Part of the Dossier	
Name of Finished Product	Volume:	:
Not applicable		
Name of Active Ingredient:	Page:	
S-217622		
<ul> <li>(4.2), and -5.9 (3.8) 72 hours post-dose, -7.4 (4.4), -7.5 (4.2), and -6.5 (3.9) 96 hours post-dose, and -8.3 (4.7), -7.9 (4.1), and -7.2 (3.9) 120 hours post-dose, respectively. There was no significant difference between either of the S-217622 treatment groups and the placebo group at any time point. However, the LS mean of the changes from baseline in total score of the 12 COVID-19 symptoms was numerically greater in the S-217622 125 mg group than in the placebo group from 12 hours post-dose onward, and in the S-217622 250 mg group than in the placebo group from 48 hours post-dose onward.</li> <li>The change from baseline in taste disorder score showed a significant difference between the S-217622 125 mg group and the placebo group at all the time points from 12 hours post-dose onward through 120 hours post-dose except for 84 hours post-dose, with the greatest p-value of 0.0347, and between the S-217622 250 mg group and the placebo group at all the time points from 24 hours post-dose onward through 120 hours post-dose except for 60 and 72 hours post-dose, with the greatest p-value of 0.0498. The change from baseline in smell disorder score showed a significant difference between the S-217622 125 mg group and the placebo group 48 to 72, 96, and 108 hours post-dose, with the greatest p-value of 0.0242, and between the S-217622 125 mg group and the placebo group 48 to 72, 96, and 108 hours post-dose, with the greatest p-value of 0.0242, and between the S-217622 125 mg group and the placebo group 48 to 72, 96, and 108 hours post-dose, with the greatest p-value of 0.0242, and between the S-217622 250 mg group and the placebo group 48 to 72, 96, and 108 hours post-dose, with the greatest p-value of 0.0242, and between the S-217622 125 mg group and the placebo group 48 to 72, 96, and 108 hours post-dose, with the greatest p-value of 0.0242, and between the S-217622 125 mg group and the placebo group 48 to 72, 96, and 108 hours post-dose, with the greatest p-value of 0.0242, and between the S-217622 125 mg</li></ul>		

#### Safety (Phase 2b Part):

In Phase 2b Part, unblinding was performed when the observation on Day 6 had been completed in the last participant of Phase 2b Part, and the safety of S-217622 was evaluated based on the results collected up to the unblinding. Efficacy and safety data continued to be collected through Day 7 and thereafter, an exploratory evaluation of the safety was performed when the observation of the follow-up period on Day 28 had been completed in all participants. In this CSR, the safety up to the unblinding is mainly described but the data collected after the unblinding are also included.

Of the 428 randomized participants (419 were Japanese), 7 participants did not receive the study intervention and was excluded from the safety analysis population. A total of 421 participants (140 each in the S-217622 125 mg and 250 mg groups and 141 in the placebo group) were included in the safety analysis population in Phase 2b Part. The safety data reported up to the unblinding (Day 6 of the last participant) of Phase 2b Part are summarized below.

- The overall incidence of TEAEs in Phase 2b Part was 26.4% (37/140) in the S-217622 125 mg group, 34.3% (48/140) in the S-217622 250 mg group, and 24.1% (34/141) in the placebo group.
- The overall incidence of treatment-related TEAEs in Phase 2b Part was 9.3% (13/140) in the S-217622 125 mg group, 18.6% (26/140) in the S-217622 250 mg group, and 5.0% (7/141) in the placebo group.
- The incidences of TEAEs were comparable between the S-217622 125 mg and placebo groups, while those were greater in the S-217622 250 mg group than in the placebo group.
- The incidences of treatment-related TEAEs were greater in either of the S-217622 treatment groups than in the placebo group.
- The incidences of TEAEs and treatment-related TEAEs were smaller in the S-217622 125 mg group than in the S-217622 250 mg group.
- The TEAEs reported in at least 2% in any of the three groups of Phase 2b Part were high density lipoprotein decreased (16.4% [23/140]) in the S-217622 125 mg group, high density lipoprotein decreased (20.0% [28/140]) and headache, diarrhoea, back pain, and hypertriglyceridaemia (2.1% [3/140] each) in the S-217622 250 mg group, and rash and high density lipoprotein decreased (2.1% [3/141] each) in the placebo group. The treatment-related TEAE reported in at least 2% in any of the three groups was high density lipoprotein decreased (5.7% [8/140] and 12.1% [17/140] in the S-217622 125 mg and 250 mg groups, respectively) only. No treatment-related TEAEs with an incidence of at least 2% were reported in the placebo group.
- No deaths or serious TEAEs were reported in the S-217622 treatment groups. Serious TEAEs were reported in 2 participants in the placebo group, both of which were considered unrelated to the study intervention.
- Three TEAEs leading to discontinuation of study intervention were reported in 2 participants in the S-217622 125 mg group, all of which were considered related to the study intervention.

Sponsor:	Individual Study	(For National
Shionogi & Co., Ltd.	Table	Authority Use only)
Shionogi B.V.	<b>Referring to Part of the Dossier</b>	
Name of Finished Product	Volume:	:
Not applicable		
Name of Active Ingredient:	Page:	
8-217622		

While the incidences of TEAEs and treatment-related TEAEs slightly increased in the safety data reported up to Day 28 of the last participant of Phase 2b Part compared with the data up to the unblinding, the safety profile of S-217622 was considered to be unchanged.

#### CONCLUSIONS

This CSR mainly reports the efficacy and safety in participants with mild/moderate SARS-CoV-2 infection using data up to the unblinding (Day 6 of the last participant) of Phase 2b Part of this study.

#### Efficacy Conclusions (Phase 2b Part):

Of the co-primary endpoints in Phase 2b Part, the change from baseline in SARS-CoV-2 viral titer on Day 4 demonstrated a statistically significantly greater decrease. However, the time-weighted average change in the total score of the 12 COVID-19 symptoms from the initiation of administration (Day 1) up to 120 hours (Day 6) failed to demonstrate a significant difference between either of the S-217622 treatment groups and the placebo group; therefore the primary objective of Phase 2b Part failed to be achieved. This could be attributed to the low baseline scores of many of the 12 COVID-19 symptoms (ie, mild symptoms with a score of less than 1) in the participants in Phase 2b Part, which made it difficult to demonstrate a significant difference between the S-217622 treatment groups and the placebo group. The following symptoms with a score of 1 or higher were considered to be specific in the participants in Phase 2b Part: low energy or tiredness, feeling hot or feverish, stuffy or runny nose, sore throat, and cough. The respiratory symptoms including some of these symptoms showed a significant improvement in either of the S-217622 treatment groups compared with the placebo group.

#### Safety Conclusions (Phase 2b Part):

In Phase 2b Part, no deaths or serious TEAEs were reported in the S-217622 treatment groups, and no specific safety issues were identified with oral administration of once-daily for 5 days (375 mg or 750 mg on Day 1 and 125 mg or 250 mg on Days 2 through 5). S-217622 was well tolerated in Phase 2b Part as well as Phase 2a Part. The safety profile of S-217622 was considered to be unchanged.

#### Date of Report: Amendment: 03 Oct 2022

Original: 01 Apr 2022